GW Pharmaceuticals

Our vision is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet needs.
GW is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy.

Type
Public
HQ
Histon, GB
Founded
1998
Size (employees)
496 (est)+28%
GW Pharmaceuticals was founded in 1998 and is headquartered in Histon, GB

GW Pharmaceuticals Office Locations

GW Pharmaceuticals has offices in Histon, London and Carlsbad
Histon, GB (HQ)
Vision Park
Carlsbad, US
210 5800 Armada Dr
London, GB
1 Cavendish Pl

GW Pharmaceuticals Data and Metrics

GW Pharmaceuticals Financial Metrics

GW Pharmaceuticals's revenue was reported to be £10.3 m in FY, 2016 which is a 64% decrease from the previous period.
£, GBP

Revenue (FY, 2016)

10.3 m

Revenue growth (FY, 2015 - FY, 2016), %

(64%)

Gross profit (FY, 2016)

7.6 m

Gross profit margin (FY, 2016), %

74%

Net income (FY, 2016)

(63.7 m)

Market capitalization (23-Jun-2017)

2.6 b

Closing share price (23-Jun-2017)

102.9

Cash (30-Sep-2016)

374.4 m
GW Pharmaceuticals's current market capitalization is $2.6 b.
£, GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

27.3 m30 m28.5 m10.3 m

Revenue growth, %

10%(5%)(64%)

Cost of goods sold

1.3 m2.1 m2.6 m2.7 m

Gross profit

26 m28 m25.9 m7.6 m

Gross profit Margin, %

95%93%91%74%

Operating expense total

36.5 m47.6 m83.2 m94.2 m

Pre tax profit

(19.6 m)(57.1 m)(86.2 m)

Net Income

(14.7 m)(44.6 m)(63.7 m)
£, GBPFY, 2014FY, 2015FY, 2016

Cash

164.5 m234.9 m374.4 m

Accounts Receivable

612 k373 k778 k

Current Assets

176.4 m255.1 m404.5 m

PP&E

11.9 m29.2 m42.8 m

Goodwill

5.2 m5.5 m5.8 m

Total Assets

193.5 m289.7 m453.2 m

Accounts Payable

2.3 m3.8 m3.4 m

Current Liabilities

17.3 m27.8 m35 m

Retained Earnings

(14.7 m)(44.6 m)(63.7 m)

Total Equity

158.6 m245.3 m398.5 m

Financial Leverage

1.2 x1.2 x1.1 x
£, GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(12.6 m)(46.5 m)(84.6 m)

Cash From Financing Activities

144.3 m128.4 m206.8 m

Income Taxes Paid

4.9 m12.5 m22.5 m
£, GBPY, 2016

Revenue/Employee

26.5 k

Financial Leverage

1.1 x

GW Pharmaceuticals Market Value History

GW Pharmaceuticals News and Updates

GW Pharmaceuticals Company Life and Culture

You may also be interested in